Which has higher valuation & earnings, PHIO or DCOY?

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is PHIO or DCOY more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -77.34% -70.87% Decoy Therapeutics N/A -395.42% -193.30%

Do analysts rate BIVI or DCOY?

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 385.04%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Decoy Therapeutics is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, BIVI or DCOY?

BioVie is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is BIVI or DCOY more profitable?

BioVie's return on equity of -101.15% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Decoy Therapeutics N/A -395.42% -193.30%

Do analysts recommend BON or DCOY?

Decoy Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 385.04%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Bon Natural Life. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, BON or DCOY?

Bon Natural Life has higher revenue and earnings than Decoy Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bon Natural Life $18.67M 0.57 -$2M N/A N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is BON or DCOY more profitable?

Bon Natural Life's return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bon Natural Life N/A N/A N/A Decoy Therapeutics N/A -395.42% -193.30%

Does the media refer more to BON or DCOY?

In the previous week, Decoy Therapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 4 mentions for Decoy Therapeutics and 3 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.38 beat Decoy Therapeutics' score of 0.37 indicating that Bon Natural Life is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bon Natural Life 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Decoy Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DCOY or LIAN?

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 385.04%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Decoy Therapeutics is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, DCOY or LIAN?

LianBio is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is DCOY or LIAN more profitable?

LianBio's return on equity of -33.17% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -395.42% -193.30% LianBio N/A -33.17% -30.19%

Do analysts prefer DCOY or FNCH?

Decoy Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 385.04%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Decoy Therapeutics is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, DCOY or FNCH?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A

Is DCOY or FNCH more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -395.42% -193.30% Finch Therapeutics Group N/A -69.14% -26.92%

Decoy Therapeutics (DCOY) Competitors

$6.18 +0.18 (+2.91%)

As of 01:09 PM Eastern

Compare

DCOY vs. PHIO, BIVI, BON, LIAN, and FNCH

Should you buy Decoy Therapeutics stock or one of its competitors? MarketBeat compares Decoy Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Decoy Therapeutics include Phio Pharmaceuticals (PHIO), BioVie (BIVI), Bon Natural Life (BON), LianBio (LIAN), and Finch Therapeutics Group (FNCH). These companies are all part of the "pharmaceutical products" industry.

How does Decoy Therapeutics compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, Decoy Therapeutics had 3 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 4 mentions for Decoy Therapeutics and 1 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 1.87 beat Decoy Therapeutics' score of 0.37 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phio Pharmaceuticals	Very Positive
Decoy Therapeutics	Neutral

Phio Pharmaceuticals' return on equity of -77.34% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Decoy Therapeutics	N/A	-395.42%	-193.30%

Phio Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 1,165.82%. Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 385.04%. Given Phio Pharmaceuticals' higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Decoy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Phio Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Summary

Phio Pharmaceuticals beats Decoy Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Decoy Therapeutics compare to BioVie?

BioVie (NASDAQ:BIVI) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

BioVie's return on equity of -101.15% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Decoy Therapeutics	N/A	-395.42%	-193.30%

BioVie is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

4.6% of BioVie shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 0.9% of BioVie shares are owned by company insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Decoy Therapeutics had 3 more articles in the media than BioVie. MarketBeat recorded 4 mentions for Decoy Therapeutics and 1 mentions for BioVie. BioVie's average media sentiment score of 1.89 beat Decoy Therapeutics' score of 0.37 indicating that BioVie is being referred to more favorably in the media.

Company	Overall Sentiment
BioVie	Very Positive
Decoy Therapeutics	Neutral

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 385.04%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Decoy Therapeutics is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioVie has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Summary

Decoy Therapeutics beats BioVie on 8 of the 13 factors compared between the two stocks.

How does Decoy Therapeutics compare to Bon Natural Life?

Bon Natural Life (NASDAQ:BON) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Bon Natural Life has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Bon Natural Life has higher revenue and earnings than Decoy Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.57	-$2M	N/A	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Bon Natural Life's return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
Decoy Therapeutics	N/A	-395.42%	-193.30%

Decoy Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 385.04%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Decoy Therapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 4 mentions for Decoy Therapeutics and 3 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.38 beat Decoy Therapeutics' score of 0.37 indicating that Bon Natural Life is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bon Natural Life	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Decoy Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by insiders. Comparatively, 1.7% of Decoy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Bon Natural Life and Decoy Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to LianBio?

Decoy Therapeutics (NASDAQ:DCOY) and LianBio (NASDAQ:LIAN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Decoy Therapeutics had 4 more articles in the media than LianBio. MarketBeat recorded 4 mentions for Decoy Therapeutics and 0 mentions for LianBio. Decoy Therapeutics' average media sentiment score of 0.37 beat LianBio's score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
LianBio	Neutral

Decoy Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 1.7% of Decoy Therapeutics shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 385.04%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Decoy Therapeutics is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

LianBio's return on equity of -33.17% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
LianBio	N/A	-33.17%	-30.19%

LianBio is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

Summary

Decoy Therapeutics beats LianBio on 8 of the 13 factors compared between the two stocks.

How does Decoy Therapeutics compare to Finch Therapeutics Group?

Decoy Therapeutics (NASDAQ:DCOY) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

Decoy Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

In the previous week, Decoy Therapeutics had 4 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for Decoy Therapeutics and 0 mentions for Finch Therapeutics Group. Decoy Therapeutics' average media sentiment score of 0.37 beat Finch Therapeutics Group's score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Finch Therapeutics Group	Neutral

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 1.7% of Decoy Therapeutics shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Decoy Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 385.04%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Decoy Therapeutics is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Finch Therapeutics Group's return on equity of -69.14% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Summary

Decoy Therapeutics beats Finch Therapeutics Group on 7 of the 13 factors compared between the two stocks.

Get Decoy Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCOY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCOY vs. The Competition

Export

Metric	Decoy Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.29M	$960.50M	$4.34B	$12.36B
Dividend Yield	N/A	4.84%	10.25%	5.67%
P/E Ratio	-0.06	1.43	22.30	24.69
Price / Sales	N/A	125.05	128.27	166.93
Price / Cash	N/A	20.06	40.19	37.92
Price / Book	0.56	8.01	25.91	6.82
Net Income	-$12.52M	-$4.88M	$116.61M	$337.45M
7 Day Performance	-1.04%	3.69%	2.03%	2.49%
1 Month Performance	40.25%	2.56%	1.98%	4.37%
1 Year Performance	N/A	49.45%	15.37%	32.80%

Decoy Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCOY Decoy Therapeutics	2.1102 of 5 stars	$6.19 +2.9%	$30.00 +385.0%	N/A	$3.29M	N/A	N/A	20	Gap Up
PHIO Phio Pharmaceuticals	3.746 of 5 stars	$1.07 -0.9%	$14.00 +1,208.4%	-52.9%	$12.55M	N/A	N/A	10	Positive News
BIVI BioVie	0.8116 of 5 stars	$1.63 -1.8%	N/A	-85.7%	$12.52M	N/A	N/A	10	Positive News
BON Bon Natural Life	1.1415 of 5 stars	$1.35 -8.8%	N/A	-11.8%	$12.03M	$18.67M	N/A	100	Positive News Short Interest Decrease Gap Up
LIAN LianBio	N/A	$0.11 +0.3%	N/A	-57.9%	$11.95M	N/A	N/A	110	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCOY) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Decoy Therapeutics (DCOY) Competitors

DCOY vs. PHIO, BIVI, BON, LIAN, and FNCH

How does Decoy Therapeutics compare to Phio Pharmaceuticals?

Summary

How does Decoy Therapeutics compare to BioVie?

Summary

How does Decoy Therapeutics compare to Bon Natural Life?

Summary

How does Decoy Therapeutics compare to LianBio?

Summary

How does Decoy Therapeutics compare to Finch Therapeutics Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Decoy Therapeutics (DCOY) Competitors

DCOY vs. PHIO, BIVI, BON, LIAN, and FNCH

How does Decoy Therapeutics compare to Phio Pharmaceuticals?

Does the media refer more to PHIO or DCOY?

Is PHIO or DCOY more profitable?

Do analysts rate PHIO or DCOY?

Do insiders and institutionals believe in PHIO or DCOY?

Which has higher valuation & earnings, PHIO or DCOY?

Which has more volatility and risk, PHIO or DCOY?

Summary

How does Decoy Therapeutics compare to BioVie?

Is BIVI or DCOY more profitable?

Which has preferable valuation and earnings, BIVI or DCOY?

Do institutionals & insiders believe in BIVI or DCOY?

Does the media refer more to BIVI or DCOY?

Do analysts rate BIVI or DCOY?

Which has more volatility & risk, BIVI or DCOY?

Summary

How does Decoy Therapeutics compare to Bon Natural Life?

Which has more volatility & risk, BON or DCOY?

Which has preferable valuation & earnings, BON or DCOY?

Is BON or DCOY more profitable?

Do analysts recommend BON or DCOY?

Does the media refer more to BON or DCOY?

Do insiders & institutionals have more ownership in BON or DCOY?

Summary

How does Decoy Therapeutics compare to LianBio?

Does the media favor DCOY or LIAN?

Which has more risk and volatility, DCOY or LIAN?

Do insiders & institutionals believe in DCOY or LIAN?

Do analysts rate DCOY or LIAN?

Is DCOY or LIAN more profitable?

Which has stronger valuation and earnings, DCOY or LIAN?

Summary

How does Decoy Therapeutics compare to Finch Therapeutics Group?

Which has stronger earnings & valuation, DCOY or FNCH?

Which has more volatility & risk, DCOY or FNCH?

Does the media prefer DCOY or FNCH?

Do institutionals and insiders have more ownership in DCOY or FNCH?

Do analysts prefer DCOY or FNCH?

Is DCOY or FNCH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools